Aug. 21 at 7:45 PM
$VRDN Lumvoa was approved on June 26, four days before its PDUFA date, and the second quarter shows what a first launch costs before it earns. Selling, general and administrative expense went from 20.2 million dollars a year earlier to 55.0 million, the net loss was 127.1 million, and cash, equivalents and marketable securities stood at 981.5 million at June 30 against 762.2 million at March 31. The gap was filled in May with about 393.8 million dollars of gross proceeds, 250.0 million of 1.75% convertible notes and 8,455,883 shares at 17.00, both over-allotments exercised in full. Next filing milestone: the elegrobart BLA, guided to the first quarter of 2027.
Free Biotech Catalyst Calendar on Merlintrader.
https://www.merlintrader.com/viridian-therapeutics-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=giro2-21ago2026
